Publication Cover
Synthetic Communications
An International Journal for Rapid Communication of Synthetic Organic Chemistry
Volume 53, 2023 - Issue 13
109
Views
1
CrossRef citations to date
0
Altmetric
Articles

Synthesis and control of process-related impurities in the β-lactamase inhibitor drug substance zidebactam

ORCID Icon, , , , , , , , & ORCID Icon show all
Pages 1041-1052 | Received 28 Mar 2023, Published online: 07 May 2023

References

  • Joshi, S.; Wankhede, K.; Jadhav, S.; Pawar, S.; Ahirrao, V.; Bhawsar, S.; Deshpande, P.; Yeole, R.; Patel, M. A. Process for Preparation of (2S,5R)-7-Oxo-6-Sulphooxy-2-[N'-((3R)-Piperidin-3-Carbonyl)Hydrazinocarbonyl]-1,6-Diaza-Bicyclo[3.2.1]Octane. U.S. Patent 9657021B2 (717/MUM/2013), WO2014/135931, September 12, 2014.
  • Patel, M.; Deshpande, P.; Bhawsar, S.; Bhagwat, S.; Jafri, M.; Mishra, A.; Pavase, L.; Gupta, S.; Kale, R.; Joshi, S. 1,6-Diaza-Bicyclo[3.2.1]Octane-7-One Derivatives and Their Use in Treatment of Bacterial Infections. U.S. Patent 20140148431A1, May 29, 2014.
  • Patel, M.; Deshpande, P.; Bhawsar, S.; Bhagwat, S.; Jafri, M.; Mishra, A.; Pavase, L.; Gupta, S.; Kale, R.; Joshi, S. 1,6-Diazabicyclo[3,2,1]Octan-7-One Derivatives and Their Use in the Treatment of Bacterial Infections. U.S, 8822450B2, September 02, 2014.
  • Papp-Wallace, K. M.; Nguyen, N. Q.; Jacobs, M. R.; Bethel, C. R.; Barnes, M. D.; Kumar, V.; Bajaksouzian, S.; Rudin, S. D.; Rather, P. N.; Bhavsar, S.; et al. Strategic Approaches to Overcome Resistance against Gram-Negative Pathogens Using β-Lactamase Inhibitors and β-Lactam Enhancers: Activity of Three Novel Diazabicyclooctanes WCK 5153, Zidebactam (WCK 5107), and WCK 4234. J. Med. Chem. 2018, 61, 4067–4086. DOI: 10.1021/acs.jmedchem.8b00091.
  • Moya, B.; Barcelo, I.; Bhagwat, S.; Patel, M.; Bou, G.; Papp-Wallace, K.; Bonomo, R.; Oliver, A. Potent β-Lactam Enhancer Activity of Zidebactam and WCK 5153 against Acinetobacter baumannii, Including Carbapenemase-Producing Clinical Isolates. Antimicrob. Agents Chemother. 2017, 61, e01238–e01317. DOI: 10.1128/AAC.01238-17.
  • ICH Guideline. Q3 (R2) Impurities in New Drug Substance; IFPMA: Geneva, 2006.
  • ICH Guideline. Q6A Specifications: Test Procedure and Acceptance Criteria for New Drug Substance and New Drug Products: Chemical Substance; IFPMA: Geneva, 1999.
  • Saravanan, M.; Kumar, K.; Reddy, P.; Satyanarayana, B. Impurity Profile Study of Venlafaxine Hydrochloride, an Antipsychotic Drug Substance. Synth. Commun. 2010, 40, 1880–1886. DOI: 10.1080/00397910903162767.
  • Rane, V.; Ahirrao, V.; Patil, K.; Jadhav, R.; Yeole, R. Impurity Profiling of a Novel β-Lactam Enhancer: Zidebactam. Chromatographia. 2020, 83, 423–437. DOI: 10.1007/s10337-019-03845-3.
  • Ahirrao, V. K.; Rane, V. P.; Patil, K. R.; Jadhav, R. A.; Bhamare, V. S.; Yadav, D. S.; Yeole, R. D. Identification of Mono-Methyl Sulfate and Sulfate Impurities in Zidebactam Using LC-MS and Application of Mixed‑Mode Liquid Chromatography with Charged Aerosol Detection and Ion Chromatography for Quantification. Chromatographia. 2020, 83, 219–228. DOI: 10.1007/s10337-019-03836-4.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.